Novo Nordisk

Novo Nordisk A/S is a global healthcare company, which engages in the the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Biopharm segments. The Diabetes and Obesity Care segment includes insulin, GLP-1 and related delivery systems, oral antidiabetic products (OAD), obesity, and other serious chronic diseases. The Biopharm segment focuses on rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1925 is headquartered in Bagsværd, Denmark.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

Novo Nordisk's drug helped reduce knee pain in osteoarthritis patients with obesity. Meanwhile, the Change Healthcare breach hit at least 100 million Americans.

Healthy Returns: Wegovy may reduce knee pain in patients with a type of arthritis and obesity

All doses of Novo Nordisk's weight loss injection Wegovy and diabetes drug Ozempic are now available in the U.S., according to an update on the FDA's drug shortage database. It is a sign that Novo Nordisk's efforts to ramp up the supply of those drugs are starting to pay off, as demand continues to skyrocket in the U.S.

Novo Nordisk's Ozempic and Wegovy now available in the U.S. after shortages, FDA says

The lowest dose of Novo Nordisk's weight-loss drug, Wegovy, was listed as available, the U.S. health regulator's website showed on Wednesday.

US FDA says lowest dose of Novo Nordisk's weight-loss drug now available

Apple

Raytheon Technologies

Apple, Novo Nordisk, RTX and FONAR are included in this Analyst Blog.

The Zacks Analyst Blog Apple, Novo Nordisk, RTX and FONAR

Eli Lilly

One key disease-prevention market is drawing closer to being within reach.

1 Huge New Reason to Buy Eli Lilly or Novo Nordisk Stock Right Now and Hold It Forever

In the latest trading session, Novo Nordisk (NVO) closed at $112.46, marking a -0.82% move from the previous day.

Novo Nordisk (NVO) Stock Falls Amid Market Uptick: What Investors Need to Know

SAN FRANCISCO--(BUSINESS WIRE)--Kivu Bioscience Raises $92 Million Series A Led by Novo Holdings to Advance Next-Generation Antibody-Drug Conjugates.

Kivu Bioscience Raises $92 Million Series A Led by Novo Holdings to Advance Next-Generation Antibody-Drug Conjugates

Novo Nordisk just released data from a clinical trial featuring its oral semaglutide treatment, Rybelsus.

This Is Huge News for Novo Nordisk (Hint: It Doesn't Involve Ozempic)

Catalent

Catalent stock faces uncertainty as several pharma companies voice concern about potential limited competition following the acquisition, especially in weight-loss drug manufacturing.

CTLT Stock Falls as Potential Hindrance to NVO Buyout Deal Increases

Lilly will launch its Mounjaro obesity drug in Denmark next week, the U.S. drugmaker said on Thursday, bringing competition to the home country of its biggest weight-loss rival, Danish pharmaceuticals group Novo Nordisk.

Lilly to launch its obesity drug in Denmark, Novo Nordisk's home market

Novo Nordisk's blockbuster diabetes drug Ozempic may reduce the risk of developing Alzheimer's disease, according to a new analysis of electronic health records. The findings suggest that Ozempic and other GLP-1 treatments could potentially delay or prevent the memory-robbing condition in patients with diabetes.

Novo Nordisk's diabetes drug Ozempic may reduce the risk of Alzheimer's disease, study says

Novo Nordisk on Tuesday asked the U.S. Food and Drug Administration to ban compounding pharmacies from making copycat versions of its popular weight-loss and diabetes drugs, which it said were too complex for those manufacturers to produce safely.

Novo Nordisk asks US to stop compounding pharmacies from making weight-loss drug copies

Novo Nordisk A/S NVO just hit a technical red flag — a Death Cross.

Novo Nordisk's Death Cross: Is A Turnaround Coming For The Ozempic, Wegovy Maker?

Novo Nordisk asked the Food and Drug Administration to prevent compounding pharmacies from making cheaper versions of its popular weight loss injection Wegovy and diabetes treatment Ozempic. The Danish drugmaker argues that the medications are too complex for those manufacturers to make safely.

Novo Nordisk asks FDA to ban compounding pharmacies from making Ozempic, Wegovy copies

Novo Nordisk (NVO) closed at $116.47 in the latest trading session, marking a -0.73% move from the prior day.

Why Novo Nordisk (NVO) Dipped More Than Broader Market Today

A late-stage study shows that Novo Nordisk's oral semaglutide, Rybelsus, cuts the risk of MACE by 14% in T2D patients compared to placebo.

NVO's Rybelsus Meets Primary Goal in MACE Study for Diabetes Patients

Biogen

Novartis

Pfizer

Regeneron Pharmaceuticals

Let us look at some big drug/biotech stocks, NVO, NVS, PFE, REGN and BIIB, which are poised to beat on third-quarter earnings.

5 Large Drug Stocks Likely to Outpace Q3 Earnings Estimates

Despite the current downward trend of Novo Nordisk, it is an excellent stock to buy for long-term gains, driven by the stellar performance of its GLP-1 drugs.

NVO Stock Falls 5% in a Month: Should Investors Buy Now or Wait?

The CHMP of the regulatory body in the EU adopts a positive opinion recommending the approval of Novo Nordisk's Alhemo for haemophilia A or B with inhibitors.

NVO's Alhemo Gets Positive CHMP Opinion in EU for Haemophilia A or B

Novo Nordisk faces growth deceleration concerns, intensified by competitive pressures from Eli Lilly and supply chain issues. NVO can improve buying sentiments by expanding its indications beyond its core weight loss and diabetes categories. NVO's growth-adjusted valuation has improved markedly, while its first-mover advantage should anchor its ability to scale profitably.

Novo Nordisk: Time To Stay Calm Amid The Recent Plunge (Rating Upgrade)

Catalent president and CEO Alessandro Maselli said on Monday he will stay on as the contract drugmaker's chief after it is acquired by Novo Holdings, the controlling shareholder of weight-loss drug manufacturer Novo Nordisk.

Catalent CEO to remain in charge of contract drugmaker after Novo Holdings' buyout

The Wegovy maker's once-daily pill to treat type 2 diabetes has shown it cuts the risk of heart attacks and strokes in patients by up to 14%, according to a new trial.

Novo Nordisk New Pill Reduces Heart Attacks, Strokes in Diabetic Patients

Novo Nordisk said on Monday an oral version of its drug semaglutide, helped significantly reduce the risk of cardiovascular events in patients in a late-stage study.

Novo Nordisk's oral diabetes drug cuts heart-related risks by 14% in study

Bagsværd, Denmark, 21 October 2024 — Novo Nordisk today announced the headline results from the SOUL cardiovascular outcomes trial. The double-blinded, randomised trial compared oral semaglutide to placebo as an adjunct to standard of care for the prevention of major adverse cardiovascular events (MACE). The trial enrolled 9,650 people with type 2 diabetes and established cardiovascular disease (CVD) and/or chronic kidney disease (CKD). As part of standard of care, 49% of patients received SGLT2i at some point during the trial.

Novo Nordisk A/S: Oral semaglutide demonstrates a 14% reduction in risk of major adverse cardiovascular events in adults with type 2 diabetes in the SOUL trial

Bagsværd, Denmark, 18 October 2024 – Novo Nordisk today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion, recommending approval of Alhemo® (concizumab) as the first once-daily subcutaneous prophylactic treatment for people aged 12 years or older living with haemophilia A or B with inhibitors.

Novo Nordisk A/S: Alhemo® recommended for European approval as first once-daily subcutaneous prophylactic treatment for people living with haemophilia A or B with inhibitors

News for Novo Nordisk Stock (NVO)